Clinical Trial

Clinical Outcomes of Bioactive Glass S53P4 in Radical Mastoid Cavity Obliteration

Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
Radical cavities resulting from open tympanoplasty performed for chronic cholesteatomatous otitis may lead to postoperative complications and negatively affect patients' quality of life. These cavities can remain unstable and may be associated with persistent otorrhea, limitations in the use of hearing aids, and the need to avoid water exposure, all of which may significantly impact daily activities. Although mastoid and paratympanic cavity obliteration techniques are increasingly used during primary surgery, many patients previously treated with open tympanoplasty continue to present with problematic postoperative cavities. Obliteration procedures have been proposed in revision surgery to improve cavity stability and reduce complications. Bioactive glass S53P4 has recently attracted interest as an obliterative material due to its long-term stability, biocompatibility, antibacterial properties, and ability to integrate with surrounding tissues. However, evidence regarding the medium-term clinical outcomes of this approach remains limited. The aim of this study is to evaluate the clinical effectiveness and safety of mastoid cavity obliteration using bioactive glass S53P4 in patients with radical cavities following open tympanoplasty. The study will assess surgical success, complication rates, and the impact of the procedure on patient quality of life.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-23.
Trial Details
NCT Number NCT07496112
Lead Sponsor Azienda Socio Sanitaria Territoriale Ovest Milanese, Ospedale di Legnano
Conditions Tympanoplasty
Enrollment 50 participants
Start Date 2025-05-01
Primary Completion 2027-05-01 (estimated)
Study Completion 2027-05-15 (estimated)
Updated on ClinicalTrials.gov 2026-04-03